GLP-1

Tirzepatide: The Complete Guide to the Dual GIP/GLP-1 Agonist

Medici

28 Apr 2026 — 6 min read

Tirzepatide has quickly become one of the most discussed medications in metabolic medicine. Sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity), it represents a new class of treatment: the dual GIP/GLP-1 receptor agonist. Unlike earlier GLP-1 drugs like semaglutide, tirzepatide activates two distinct hormonal pathways simultaneously — and the clinical results have been remarkable.

This guide covers everything you need to know: how tirzepatide works at a molecular level, what the clinical trials actually showed, how to dose it safely, how it compares to semaglutide, and the current legal landscape around compounded versions.

What Is Tirzepatide?

Tirzepatide is a synthetic 39-amino acid polypeptide developed by Eli Lilly. It was approved by the FDA in May 2022 for type 2 diabetes (Mounjaro) and in November 2023 for chronic weight management (Zepbound). It is administered as a once-weekly subcutaneous injection.

Its defining feature is dual agonism: tirzepatide simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This distinguishes it from semaglutide, liraglutide, and other pure GLP-1 agonists.

Mechanism of Action: How Tirzepatide Works

The GLP-1 Pathway

GLP-1 is an incretin hormone released from the gut in response to food intake. When tirzepatide activates GLP-1 receptors, it:

Stimulates glucose-dependent insulin secretion from pancreatic beta cells
Suppresses glucagon release, reducing hepatic glucose output
Slows gastric emptying, prolonging satiety
Acts on hypothalamic appetite centers to reduce hunger signals

The GIP Pathway — The Key Differentiator

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, and it was historically considered less important for weight loss. Tirzepatide changed that assumption dramatically.

GIPR activation by tirzepatide contributes to:

Potentiated insulin secretion (GIP and GLP-1 work synergistically)
Enhanced fat storage regulation in adipose tissue
Additional appetite suppression beyond GLP-1 alone
Possible cardioprotective effects via direct cardiac GIPR signaling

Tirzepatide is described in the scientific literature as an imbalanced agonist — it has higher affinity and potency at the GIPR than at GLP-1R. It also shows biased agonism toward the cAMP pathway at GLP-1R, which may optimize its metabolic efficacy beyond what simple receptor binding would predict.

Clinical Trial Results

SURPASS Trials: Type 2 Diabetes

The SURPASS program (SURPASS-1 through SURPASS-5) evaluated tirzepatide across diverse patient populations with type 2 diabetes. Key findings:

SURPASS-2: Tirzepatide at 15 mg reduced HbA1c by 2.46% versus 1.86% for semaglutide 1 mg — a statistically significant advantage
SURPASS-3 and -4: Tirzepatide outperformed both insulin degludec and insulin glargine for glycemic control, while producing weight loss rather than the weight gain typically associated with insulin therapy
All three doses (5 mg, 10 mg, 15 mg) were superior to placebo and active comparators across all five pivotal trials

SURMOUNT Trials: Obesity Without Diabetes

The SURMOUNT program tested tirzepatide in people with obesity or overweight without diabetes:

SURMOUNT-1: At 72 weeks, tirzepatide 10 mg and 15 mg produced mean weight reductions of 19.5% and 20.9%, respectively, compared to just 3.1% with placebo
SURMOUNT-4: Patients who discontinued tirzepatide after 36 weeks regained approximately 14% of body weight over the following year, while those who continued lost an additional 5.5% — confirming that ongoing treatment is required to maintain results

SURMOUNT-5: The Head-to-Head vs. Semaglutide

The most significant trial for patients making a treatment decision is SURMOUNT-5, published in the New England Journal of Medicine in 2025. This was the first direct, head-to-head comparison of tirzepatide (Zepbound) versus semaglutide (Wegovy) for obesity over 72 weeks in 751 patients. Results were decisive:

Tirzepatide: −20.2% mean body weight loss (approximately 50.3 lbs)
Semaglutide: −13.7% mean body weight loss (approximately 33.1 lbs)
31.6% of tirzepatide patients achieved ≥25% body weight loss versus only 16.1% with semaglutide
Tirzepatide produced significantly greater reductions in waist circumference and predicted 10-year cardiovascular disease risk
Safety profiles were similar between groups, with GI side effects the most common in both

Dosing Guide: The Standard Titration Schedule

Tirzepatide is always initiated at a low dose and increased gradually to minimize gastrointestinal side effects. The standard progression used in clinical practice and approved labeling:

Weeks 1–4: 2.5 mg weekly — tolerance building; not intended to produce significant weight loss
Weeks 5–8: 5 mg weekly — first therapeutic dose
Weeks 9–12: 7.5 mg weekly
Weeks 13–16: 10 mg weekly
Weeks 17–20: 12.5 mg weekly
Week 21+: 15 mg weekly — maximum approved maintenance dose

Key dosing rules:

Dose increases occur no more frequently than every 4 weeks
Each increment is exactly 2.5 mg — never skip dose levels
Administer via subcutaneous injection in the abdomen, thigh, or upper arm; rotate sites weekly
Choose any day of the week and stay consistent
If a dose is missed more than 4 days late, skip it and resume on the next scheduled day

Tips for tolerability during dose escalation:

Eat smaller, more frequent meals rather than 2–3 large ones
Avoid high-fat or greasy foods around injection time
Stay well hydrated throughout the week
Consider administering at bedtime so peak GI effects occur during sleep

Side Effects and Safety Profile

Common (More Than 10% Incidence)

Nausea — most frequent during dose escalation; improves substantially at steady-state maintenance doses
Diarrhea
Vomiting
Constipation
Abdominal discomfort or pain

Less Common but Clinically Relevant

Hypoglycemia: Risk is elevated when tirzepatide is combined with insulin or sulfonylureas; dose reduction of those agents is typically required when starting tirzepatide
Injection site reactions: Typically mild and transient
Heart rate increase: Average of 2–4 bpm above baseline; generally not clinically significant
Acute pancreatitis: Rare but reported; discontinue immediately if severe abdominal symptoms occur
Acute kidney injury: Usually secondary to dehydration from GI side effects; stay hydrated

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or intention to become pregnant
Known hypersensitivity to tirzepatide or any excipient

Tirzepatide vs. Semaglutide: Which Is Right for You?

Both belong to the incretin class but differ in mechanism, efficacy depth, and evidence maturity:

Mechanism: Tirzepatide is a dual GIP + GLP-1 agonist. Semaglutide activates GLP-1 receptors only.

Average weight loss: Tirzepatide produces approximately 20% body weight reduction in clinical trials. Semaglutide produces 13–15%.

Cardiovascular outcomes: Semaglutide has established data from the SELECT trial demonstrating a 20% reduction in major cardiovascular events in patients with existing cardiovascular disease. Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is ongoing as of 2025.

Side effect profile: Both medications produce similar GI side effects. Individual tolerability varies — some patients do better on one versus the other, and this cannot be predicted in advance.

Bottom line: If maximal weight loss is the primary goal and cardiovascular disease is not a primary concern, tirzepatide has a clear advantage based on current evidence. If established cardiovascular risk reduction is the priority, semaglutide remains the better-supported choice until SURPASS-CVOT reports data.

Compounded Tirzepatide: The 2025–2026 Legal Landscape

Throughout 2023–2024, both 503A state-licensed pharmacies and 503B outsourcing facilities could legally compound tirzepatide because the branded product appeared on the FDA's drug shortage list. That window has effectively closed:

December 19, 2024: FDA determined the tirzepatide shortage was resolved
February 18, 2025: Enforcement discretion ended for 503A pharmacies — routine compounded tirzepatide copies became prohibited
March 19, 2025: 503B outsourcing facilities lost all authority to compound tirzepatide
May 7, 2025: A federal court upheld the FDA's shortage determination in Outsourcing Facilities Association v. FDA, removing the last meaningful legal challenge

A narrow 503A exception still exists: compounding is permitted only when (1) there is a valid individual prescription from a licensed prescriber, (2) the prescriber has documented a specific clinical justification — such as a documented allergy to an inactive ingredient in the commercial product, or a specific clinical need the approved product cannot meet — and (3) the pharmacy is a verifiable state-licensed 503A facility using the approved tirzepatide form.

For the vast majority of patients, compounded tirzepatide is no longer a legal or practically accessible option. Patients should work with licensed prescribers to obtain Mounjaro or Zepbound through standard pharmacy channels.

Practical Patient Tips

Storage: Tirzepatide pens must be refrigerated at 36–46°F (2–8°C). They may be kept at room temperature up to 86°F (30°C) for a maximum of 21 days. Never freeze. Protect from direct light. Inspect visually before each use — the solution should be clear and colorless to slightly yellow.

When to expect results: Clinically meaningful weight loss typically becomes apparent around weeks 4–8, when you first reach the 5 mg therapeutic dose. The greatest acceleration in weight loss occurs during weeks 8–20 as doses increase. Most SURMOUNT trial primary endpoints were assessed at 72–88 weeks — set realistic expectations and treat this as a long-term intervention.

Cost and access: Without insurance, Zepbound runs approximately $550–$650 per month at US pharmacies. Lilly's savings card can significantly reduce out-of-pocket costs for commercially insured patients. Medicare Part D coverage for obesity medications remains limited for many beneficiaries under current law.

Conclusion

Tirzepatide marks a genuine step forward in obesity pharmacotherapy. Its dual GIP/GLP-1 mechanism delivers weight loss outcomes that consistently outperform earlier GLP-1 agonists, and the SURMOUNT-5 head-to-head trial against semaglutide cemented its position as the most effective FDA-approved medication for obesity currently available.

Results depend on adherence, dietary patterns, and individual biology. The careful titration schedule exists for practical reasons — moving too quickly increases side effects and leads to unnecessary discontinuation. For patients who tolerate and maintain treatment at full therapeutic doses, tirzepatide offers clinically meaningful reductions in body weight, metabolic risk markers, and likely long-term cardiovascular risk.

Always consult a licensed prescriber to determine whether tirzepatide is appropriate for your situation, develop a safe titration plan, and monitor for side effects over time.